Briefing · compiled August 2026 · every claim sourced
Dual agency: the company paying for the session increasingly directs it
Psychiatric patients whose care went through utilization management were 2.6 times more likely to have their treatment plans modified, and the changes trended away from guideline-concordant care (Mintz et al., American Journal of Psychiatry, 2004). Two decades later, the corporations performing that review increasingly share an owner with the clinician's billing platform, the member's insurance plan, or both. This briefing maps those relationships and treats them the way medical ethics treats them: as dual agency, a conflict inside the clinical relationship, rather than a business story.
The ethics question is older than the platforms
The professional codes are explicit. The AMA Code of Medical Ethics states that when a patient's welfare conflicts with the economic interests of "the hospital, health care organization, or other entity," patient welfare prevails (Opinion 11.2.2). The psychologists' code requires clarifying and resolving conflicts between the code and organizational demands in the client's favor (APA Standards 1.03 and 3.06), and the social workers' code carries the same duty toward employers (NASW 3.09). Sabin and Daniels named the underlying problem in 1994: a clinician asked to serve the patient and the payer at once is practicing "double agentry," and the psychiatric ethics code was written for the first role (Behavioral Sciences & the Law, 1994).
While the ethics literature framed dual agency as a tension inside the clinician, the ownership structures below move the second agent outside the room. The clinician's platform, the reviewer of the chart, and the payer of the claim can now be one corporate family.
One corporate family can hold four positions in a session
- UnitedHealth Group operates the payer (UnitedHealthcare), delivers care (Optum Behavioral Health, Refresh, and wholly owned virtual provider AbleTo, to which UHC routed more than 5 million of its own members in 2023), and holds platform equity: Optum Ventures invested in Alma, a stake that Oregon regulators note converts into the merged Spring Health.
- Elevance operates Anthem plans and owns Carelon Behavioral Health, the country's largest behavioral utilization-management company, alongside care delivery and a PBM.
- The Cigna Group sets rates as Cigna, performs behavioral utilization management as Evernorth, owns the MDLIVE delivery platform its CEO describes matching members to therapists, and held Alma equity through Cigna Ventures that likewise converts into Spring Health.
- Blue Cross Blue Shield plans hold platform equity directly: HCSC, the Blues plan for five states, led the strategic investment in Headway's Series C and credits the relationship with a 5% reduction in inpatient behavioral admissions in Texas (HCSC, 2023); the BCBS-affiliated Blue Venture Fund lists Rula and AbleTo in its portfolio.
Accordingly, a therapist on a platform can face a rate set by an insurer, a chart review run by that insurer's subsidiary, and a platform whose investors include that same insurer, in a single case.
Documented reaches into the session
Session-count review, in writing. Rula's own Clinical Care Review policy, filed as an exhibit in a union complaint to California's managed-care regulator, describes concurrent utilization review "only in place for clients covered by Kaiser SoCal": completed before the 16th visit, typically after session 13, and every 10 visits after, drawing on PHQ and GAD scores. The complaint alleges enrollees are not told their care is under review and receive no denial notices (NUHW complaint to DMHC, February 2024). These are allegations under regulatory review; the policy language is quoted from Rula's document.
Outlier algorithms. United Behavioral Health's ALERT program flagged psychotherapy around the twentieth session for review; New York's attorney general and the US Department of Labor settled with UBH for about $14.3 million in 2021, and UBH agreed to stop using ALERT (Kennedy Forum summary). ProPublica reported in 2024 that Optum still ran an outlier program flagging therapy beyond roughly 30 sessions in 8 months, deemed illegal in three states and continued elsewhere (ProPublica, November 2024).
Guidelines shaped by finances. In Wit v. United Behavioral Health, the district court found UBH's level-of-care guidelines were inconsistent with generally accepted standards and were shaped by financial interests; after reversals and remands, the court held in August 2025 that fiduciary-breach claims over the 2011–2017 guidelines remain viable (case coverage; status tracker).
Session-length pressure. Anthem and Highmark sent letters in 2016–2017 to clinicians who billed 60-minute sessions more than peers; after the APA intervened, Anthem stated in writing the letters were educational and not meant to dissuade 90837 use (APA Services). Therapists continued reporting such letters from UnitedHealthcare in August 2026, alongside colleagues describing deliberate downcoding to avoid flags (community reports). The reported 2024 platform rate cuts on Optum contracts, and the 2026 Alma change paying 90837 at 90834 rates, move the same lever through economics; those rows are in the table.
Outcome data leaving the room. BuzzFeed News reported in 2022 that Lyra paid productivity-based bonuses tied to caseload turnover and shared anonymized outcome data with employer clients; six of the eight therapists interviewed did not know (BuzzFeed News, 2022). The Kaiser–Rula review process described above likewise draws on PHQ and GAD scores, instruments designed for care, used for coverage.
What the ownership research shows
Private equity owned 6.2% of US mental-health facilities and 7.1% of substance-use facilities as of 2021, with several states above 20% (Zhu et al., JAMA Psychiatry, 2024), and about 14% of psychiatric hospitals (Shields et al., JAMA Psychiatry, 2025). Behavioral-health outcome data under investor ownership is thin; the adjacent evidence raises concerns. In nursing homes, private-equity ownership was associated with about 10% higher short-term mortality and reduced staffing (Gupta et al., Review of Financial Studies, 2024), and caregivers rated investor-owned hospices below nonprofits on communication and symptom care (JAMA, 2024). These are observational findings from other settings; they cannot establish what investor ownership does to psychotherapy. However, the one behavioral pattern that is documented is exits: an analysis of 70 behavioral entities Optum acquired found half of their locations closed, including a complete New Jersey withdrawal with 572 layoffs (Health Care un-covered, 2026; layoff reporting).
The enforcement layer is thinning
The federal parity report to Congress found widespread noncompliance in how plans set behavioral reimbursement and build networks (DOL/Treasury/HHS, January 2025). Four months later, after an industry lawsuit, the departments announced they would not enforce the 2024 parity rule's new requirements while they reconsider it (May 2025 statement). Directory enforcement is moving in the other direction: after the Senate Finance Committee's secret shoppers reached a bookable behavioral appointment on 18% of calls (2023 study) and New York's attorney general found 86% of listed in-network providers unavailable, New York settled with MVP and EmblemHealth, the American Psychiatric Association filed a class action over ghost networks in January 2026 (APA), and federal directory-accuracy requirements for Medicare Advantage begin in 2028. California's SB 1120 now bars plans from letting an algorithm supplant a clinician's medical-necessity decision (effective January 2025).
What this means in the room
Three questions tell a clinician where the second agent sits. First, who performs utilization review on your contract, and who owns them; the company pages map the ownership chains. Second, whether outcome measures you administer leave the treatment relationship, and under what name; a measure used for coverage decisions is no longer only a clinical instrument. Third, what your session-length economics reward: the rate table shows what each payer and route pays for a 90837 against a 90834, which is where the pressure lands first. Parity complaints go to the Department of Labor for employer plans and to state regulators for the rest, and Wit established that guideline-based denials can be challenged.
Limitations
This briefing has four limitations. First, several items are allegations in complaints or lawsuits, not adjudicated findings, and are labeled as such; Anthem stated its 90837 letters were educational, and the Kaiser–Rula review process is before a regulator. Second, the ownership-outcome studies are observational and mostly from adjacent settings; the results cannot establish causal relationships in psychotherapy. Third, equity stakes documented at investment or merger may change without public record. Fourth, community reports are self-selected. Nevertheless, the policy documents, court findings, settlements, and the companies' own announcements cited here are a public record that the paying and directing roles in therapy are consolidating, and that consolidation is the thing to keep watching.
Corrections are welcome through the submission form. Related briefings: the insurer on both sides · platform economics · data and AI.